Rapid Biosensor Systems to launch breathalyzer test
This article was originally published in The Gray Sheet
Executive Summary
Rapid Biosensor Systems is planning an initial March debut of its TB Breathalyzer, a light-weight, portable, non-invasive screening device for early-stage tuberculosis. While initial launches will be in India and South Africa, the Cambridge, England, company says it will simultaneously begin the approval processes with FDA and Great Britain's Medicines and Healthcare Products Regulatory Agency. The breathalyzer delivers a positive or negative result with 95% accuracy within minutes, as opposed to the most prevalent test for TB in use, the Mantoux TB test, which involves a 72-hour wait time, according to the company